Healthcare most active stocks: Orexigen Therapeutics (NASDAQ:OREX), Express Scripts Holding (NASDAQ:ESRX), Karyopharm Therapeutics Inc (NASDAQ:KPTI), Novavax (NASDAQ:NVAX), Bristol-Myers Squibb (NYSE:BMY)



According to a statement of Orexigen Therapeutics, Inc. (NASDAQ:OREX), the U.S Food and Drug Administration hasn’t given a green signal to its new drug which helps people in fighting from obesity. One of the spokespersons of the company said,” FDA has delayed its decision on our drug for as much as 3 months. So we will be able to get a final call only after three months’ time.” Orexigen Therapeutics, Inc. (NASDAQ:OREX) stock performance was 3.08% in last session and finished the day at $5.85. Traded volume was 4.86million shares in the last session and the average volume of the stock remained 3.14million shares. The beta of the stock remained 2.62. Orexigen Therapeutics, Inc. (NASDAQ:OREX) insider ownership is 11.49%.

Shares of Express Scripts Holding Company (NASDAQ:ESRX) were the recipient of a significant increase in short interest in the month of May. As of May 30th, there was short interest totalling 15,725,181 shares, an increase of 8.5% from the May 15th total of 14,489,826 shares. Express Scripts Holding Company (NASDAQ:ESRX) rose 0.03 percent to $71.59 Friday on volume of 5.11million shares. The intra-day range of the stock was $70.85 to $71.81. Express Scripts Holding Company (NASDAQ:ESRX) has a market capitalization of $55.52billion.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) announced initial Phase 1 data from patients with multiple myeloma treated with Selinexor, in combination with “low-dose” dexamethasone Friday morning. Karyopharm Therapeutics Inc (NASDAQ:KPTI)’s stock on June 13, 2014 reported a increase of 93.51% to the closing price of $47.12. Its fifty two weeks range is $15.50 -$47.98. The total market capitalization recorded $1.40billion. The overall volume in the last trading session was 5.93million shares. In its share capital, KPTI has 29.76million outstanding shares.

Novavax, Inc. (NASDAQ:NVAX) on June 11 announced the closing of the underwritten public offering priced on Thursday, June 5, 2014. The company issued 28,750,000 shares of its common stock, including 3,750,000 shares pursuant to the underwriters’ option to purchase additional shares. On Friday, shares of Novavax, Inc. (NASDAQ:NVAX) dropped -1.54% to close the day at $4.48. Company return on investment (ROI) is -25.50% and its monthly performance is recorded as 5.41%.  Novavax, Inc. (NASDAQ:NVAX) quarterly revenue growth is -16.57%.

The Federal Circuit on Wednesday affirmed a lower court’s decision that a Bristol-Myers Squibb Co. (NYSE:BMY) patent covering the hepatitis B drug Baraclude is invalid as obvious because it made only minor changes to the prior art, in a win for generics maker Teva Pharmaceuticals USA Inc. Bristol-Myers Squibb Co (NYSE:BMY) stock performance was 0.45% in last session and finished the day at $47.09. Traded volume was 6.28million shares in the last session and the average volume of the stock remained 9.06million shares. The beta of the stock remained 0.48. Bristol-Myers Squibb Co (NYSE:BMY) insider ownership is 0.10%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone